Related Experiment Video
Updated: Jul 30, 2026
13:59
Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
Published on: October 9, 2010
Genetic Polymorphisms in ADORA2A and CYP1A2 Influence Caffeine's Effect on Postprandial Glycaemia
N F Banks1,2, P M Tomko1,2, R J Colquhoun1,2
1Applied Neuromuscular Physiology Laboratory, Oklahoma State University, Stillwater, OK, USA.
Scientific Reports
|July 21, 2019
Summary
Genetic variations in caffeine metabolism (CYP1A2) and caffeine
Area of Science:
- Pharmacogenomics
- Nutritional Science
- Metabolic Research
Background:
- Caffeine metabolism is primarily mediated by the liver enzyme cytochrome P450 1A2 (CYP1A2).
- Caffeine's physiological effects, including its interaction with adenosine A2a receptors (ADORA2A), are well-documented.
- Individual responses to caffeine can vary due to genetic factors.
Purpose of the Study:
- To investigate the influence of specific single nucleotide polymorphisms (SNPs) in ADORA2A (rs5751876) and CYP1A2 (rs762551) on postprandial glucose response to caffeine.
- To determine if genetic variations affect how caffeine impacts blood glucose levels after a carbohydrate meal.
Main Methods:
- Genotyping for ADORA2A (1976T>C) and CYP1A2 (-163C>A) functional SNPs.
- Measuring postprandial glucose (GLU) levels in participants consuming a carbohydrate meal with or without caffeine.
- Comparing GLU area under the curve (AUC) and 60-minute postprandial GLU concentrations between genotypes and conditions (CHO vs. CHO+CAFF).
Main Results:
- Individuals with the ADORA2A CC genotype (rs5751876) showed elevated postprandial glucose levels and AUC when consuming caffeine with carbohydrates.
- Participants with the CYP1A2 AC/CC genotypes (rs762551) exhibited higher 60-minute glucose concentrations after the CHO+CAFF meal compared to the CHO-only meal.
- The study identified specific genotypes in ADORA2A and CYP1A2 associated with caffeine's impact on postprandial glucose.
Conclusions:
- Functional SNPs in ADORA2A (1976T>C) and CYP1A2 (-163C>A) are associated with caffeine-induced alterations in postprandial glucose metabolism.
- Genetic variations in caffeine-related genes may explain inter-individual differences in glucose response to caffeine consumption.
- These findings highlight the role of pharmacogenetics in understanding caffeine's metabolic effects.
More Related Videos
09:11Caffeine Extraction, Enzymatic Activity and Gene Expression of Caffeine Synthase from Plant Cell Suspensions
Published on: October 2, 2018
04:54Using a Combination of Indirect Calorimetry, Infrared Thermography, and Blood Glucose Levels to Measure Brown Adipose Tissue Thermogenesis in Humans
Published on: June 2, 2023
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...